Copyright
©The Author(s) 2017.
World J Hematol. Feb 6, 2017; 6(1): 1-10
Published online Feb 6, 2017. doi: 10.5315/wjh.v6.i1.1
Published online Feb 6, 2017. doi: 10.5315/wjh.v6.i1.1
Patient | Sex | Age at ASCT (yr) | Disease phase at ASCT | Time from diagnosis to ASCT (mo) | Indication for ASCT | Donor sex |
1 | M | 22 | 1st AP | 50 | Resistance to imatinib and clonal evolution | M |
2 | F | 51 | 2nd CP | 14 | Previous myeloid blastic phase | M |
3 | M | 25 | 2nd CP | 61 | Previous lymphoid blastic phase | M |
4 | M | 33 | 1st CP | 37 | Resistance to imatinib and dasatinib | M |
5 | F | 54 | 1st AP | 103 | Resistance to imatinib, nilotinib and dasatinib 1st accelerated phase | F |
6 | M | 65 | 1st CP | 133 | Resistance to imatinib and nilotinib | F |
7 | F | 49 | 1st CP | 62 | Resistance to imatinib | M |
8 | M | 53 | 2nd CP | 63 | Previous myeloid blastic phase | M |
9 | M | 41 | 1st CP | 51 | Resistance to imatinib | M |
10 | M | 61 | 1st CP | 75 | Resistance to imatinib, nilotinib and dasatinib | F |
- Citation: Soyer N, Uysal A, Tombuloglu M, Sahin F, Saydam G, Vural F. Allogeneic stem cell transplantation in chronic myeloid leukemia patients: Single center experience. World J Hematol 2017; 6(1): 1-10
- URL: https://www.wjgnet.com/2218-6204/full/v6/i1/1.htm
- DOI: https://dx.doi.org/10.5315/wjh.v6.i1.1